Australia Examines Potential Conflicts Of Interest For Government Medical Advisers
This article was originally published in PharmAsia News
The links between Australian government medical advisors and pharmaceutical firms have come under close scrutiny following incidents of adverse reactions to children's flu shots
You may also be interested in...
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.